All of Transgene’s preclinical and clinical assets progressed in line with expectations in Q1 2022

information fournie par Boursorama CP •10/05/2022 à 17:45

-­ TG4050 – New positive preliminary Phase I results presented at AACR 2022; additional clinical data to be presented at ASCO 2022
­
- BT-001 – Preclinical data presented at AACR 2022. Phase I clinical update to be released in Q2 2022

­- Dr. Alessandro Riva proposed as new independent Director and non-executive Chairman of the Board, separating the roles of Chairman and Chief Executive Officer

­- €46.8 million in cash and cash equivalents as of March 31, 2022 – Confirmed financial visibility until the end of 2023

.../...